BiotechTube

ISV-305

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Active, Symptomatic Blepharitis

Conditions

Active, Symptomatic Blepharitis

Trial Timeline

Mar 30, 2018 → Feb 4, 2020

NCT ID
NCT01543490

About ISV-305

ISV-305 is a phase 3 stage product being developed by Sun Pharmaceutical for Active, Symptomatic Blepharitis. The current trial status is completed. This product is registered under clinical trial identifier NCT01543490. Target conditions include Active, Symptomatic Blepharitis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (3)

NCT IDPhaseStatus
NCT01543490Phase 3Completed
NCT03192137Phase 3Completed
NCT03192150Phase 3Completed

Competing Products

20 competing products in Active, Symptomatic Blepharitis

See all competitors
ProductCompanyStageHype Score
CT-P13 SC Auto-Injector + Placebo Auto-InjectorCelltrionPhase 3
77
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
mirabegron + solifenacinAstellas PharmaApproved
85
CDP870Astellas PharmaPhase 3
77
Mirabegron + PlaceboAstellas PharmaApproved
85
SolifenacinAstellas PharmaApproved
85
Mirabegron + Tolterodine + Placebo to Mirabegron + Placebo to TolterodineAstellas PharmaPhase 3
77
solifenacin succinateAstellas PharmaPhase 3
77
SolifenacinAstellas PharmaPre-clinical
23
BetanisAstellas PharmaPre-clinical
23
SolifenacinAstellas PharmaApproved
85
SolifenacinAstellas PharmaPhase 2
52
Mirabegron + Tolterodine ERAstellas PharmaApproved
85
mirabegron + solifenacin + darifenacin + imidafenacin + tolterodine + oxybutynin + trospium + fesoterodine + propiverineAstellas PharmaPre-clinical
23
Alpha blocker + placebo + solifenacinAstellas PharmaApproved
85
warfarin + YM178Astellas PharmaPhase 1
33
Solifenacin succinateAstellas PharmaPhase 3
77
solifenacin succinate + tolterodineAstellas PharmaPhase 3
77

Other Products from Sun Pharmaceutical

Ilumya Injectable ProductApproved
85
CequaTM (Cyclosporine 0.09%) ophthalmic solutionApproved
85
Cyclosporine + Artificial tearApproved
85
AmifostineApproved
85
Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy + Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapyApproved
85